| ID Source | ID |
|---|---|
| PubMed CID | 219402 |
| CHEMBL ID | 1701761 |
| SCHEMBL ID | 17964191 |
| MeSH ID | M0046169 |
| Synonym |
|---|
| smr001547064 |
| reulatt s.s. |
| gluronsan |
| d-glucurono-.gamma.-lactone |
| d-glucuronic acid, .gamma.-lactone |
| glucofuranuronic acid, d- |
| mls002637528 , |
| glucuronic acid .gamma.-lactone |
| glucuronic acid lactone |
| d-glucuronic acid .gamma.-lactone |
| glucuronosan |
| glucurolactone |
| 32449-92-6 |
| guronsan |
| d-glucuronic acid lactone |
| glycurone |
| d-glucofuranuronic acid, .gamma.-lactone |
| glucurone |
| glucoxy |
| glucuron |
| d-glucurono-6,3-lactone |
| nsc656 |
| nsc-656 |
| 31C335D8-E210-447C-9CBF-AE575A9BC94A |
| glucuronic acid-3,6-lactone |
| FT-0693376 |
| 2-(3,4-dihydroxy-5-oxooxolan-2-yl)-2-hydroxyacetaldehyde |
| NCGC00246859-01 |
| FT-0624570 |
| .gamma.-glukurolakton |
| UYUXSRADSPPKRZ-UHFFFAOYSA-N |
| glucofuranuronic acid, .gamma.-lactone, d- |
| glucuronic acid, .gamma.-lactone, d- |
| CHEMBL1701761 |
| bdbm83202 |
| cid_219402 |
| 2-(3,4-dihydroxy-5-oxo-2-oxolanyl)-2-hydroxyacetaldehyde |
| 2-(3,4-dihydroxy-5-keto-tetrahydrofuran-2-yl)-2-hydroxy-acetaldehyde |
| 2-[3,4-bis(oxidanyl)-5-oxidanylidene-oxolan-2-yl]-2-oxidanyl-ethanal |
| SCHEMBL17964191 |
| (2r)-2-[(3r,4s)-3,4-dihydroxy-5-oxooxolan-2-yl]-2-hydroxyacetaldehyde |
| 14474-04-5 |
| d-glucurono-6,3-lactone;d-glucuronic acid (c)(3/4)-lactone;glucurolactone |
| BCP13490 |
| 7330-12-3 |
| l-gulurono-6,3-lactone |
| d-galacturono-6,3-lactone |
| DTXSID40872006 |
| (3,4-dihydroxy-5-oxooxolan-2-yl)(hydroxy)acetaldehyde (non-preferred name) |
| d-glucuronic-acid-lactone |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 22.3872 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| GLS protein | Homo sapiens (human) | Potency | 11.2202 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 23.7781 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 79.4328 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 7.9433 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 44.6684 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 50.1187 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 3.1623 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 4.7852 | 0.0757 | 8.4742 | 29.0628 | AID602233; AID686980 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| DNA (cytosine-5)-methyltransferase 1 isoform b | Homo sapiens (human) | IC50 (µMol) | 14.4000 | 1.2900 | 8.7555 | 41.0000 | AID602386 |
| carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 4.0520 | 2.0580 | 8.2052 | 41.3880 | AID540297 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| protein binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| cAMP binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| protein-macromolecule adaptor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| small GTPase binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| hippocampal mossy fiber to CA3 synapse | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||